T. Kerbusch
Department of Pharmacy and Pharmacology
The Netherlands Cancer Institute/ Slotervaart Hospital
Amsterdam
Name/email consistency: high
- Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Kerbusch, T., de Kraker, J., Keizer, H.J., van Putten, J.W., Groen, H.J., Jansen, R.L., Schellens, J.H., Beijnen, J.H. Clin. Pharmacokinet (2001)
- Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Kerbusch, T., Mathôt, R.A., Keizer, H.J., Kaijser, G.P., Schellens, J.H., Beijnen, J.H. Drug Metab. Dispos. (2001)
- Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients. Kerbusch, T., vanPutten, J.W., Groen, H.J., Huitema, A.D., Mathĵt, R.A., Beijnen, J.H. Cancer Chemother. Pharmacol. (2001)
- Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Kerbusch, T., Jansen, R.L., Mathôt, R.A., Huitema, A.D., Jansen, M., van Rijswijk, R.E., Beijnen, J.H. Clin. Pharmacol. Ther. (2001)
- Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Kerbusch, T., de Kraker, J., Mathĵt, R.A., Beijne, J.H. Clin. Pharmacokinet (2001)
- Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. Kerbusch, T., Mathĵt, R.A., Keizer, H.J., Ouwerkerk, J., Rodenhuis, S., Schellens, J.H., Beijnen, J.H. Eur. J. Clin. Pharmacol. (2001)
